Use of β-1,3 / α-1,3-glucan in the preparation of drugs for treating or / and preventing allergic diseases

By using oral preparations prepared by β-1,3/α-1,3-glucan, the side effects and difficulties in using existing allergic diseases treatment drugs have been solved, and effective treatment of asthma and pollen allergies has been achieved. The effect is comparable to dexamethasone and loratadine and is safer.

CN118750509BActive Publication Date: 2024-11-19TIANJIN UBASIO NATURAL PROD TECH CO LTD +1
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411256802.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-19
Estimated Expiration
2044-09-09

AI Technical Summary

Technical Problem

Existing allergic diseases treatment drugs, such as dexamethasone and loratadine, have side effects and adverse reactions, and are difficult to bind to glucocorticoid receptors through the cell membrane, and cannot be effectively used for atomized inhalation treatment, and may be used for long-term use. Causes drug resistance.

Method used

β-1,3/α-1,3-glucan is used as an active ingredient and combined with pharmaceutically acceptable excipients to prepare an oral preparation for the treatment or prevention of allergic diseases, especially asthma and pollen allergies.

Benefits of technology

When taking the drug at high doses, it is comparable to dexamethasone and loratadine, and is safer in clinical use, significantly reducing the serum Ig E, IL-4 and TNF-α content of rats with asthma and pollen allergic, and improving the alveolar vesicula. The cell count in the lavage solution has significant efficacy and fewer side effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides the use of β-1,3 / α-1,3-glucan in preparing a drug for treating or / and preventing allergic diseases, and belongs to the field of medicine. The β-1,3 / α-1,3-glucan of the present invention is used for treating or / and preventing allergic diseases, has clear efficacy, and high-dose β-1,3 / α-1,3-glucan has equivalent efficacy to dexamethasone, and is safer for clinical use.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to use of beta-1,3 / alpha-1,3-glucan in preparing medicines for treating and / or preventing allergic diseases, and belongs to the field of medicines. Background Art

[0002] Allergic diseases are a type of common and frequently occurring allergic diseases. According to the 2013 World Allergy Organization White Paper, the global prevalence of allergic diseases is 10-40%, including 400 million patients with allergic rhinitis and 300 million patients with bronchial asthma. The 2022 China Allergic Disease Epidemiological Survey Report and Current Situation Analysis shows that more than 40% of infants and young children in my country suffer from allergies. In the past decade, the prevalence of eczema in children in my country has increased by about 4.65 times, the number of outpatient visits for allergic rhinitis has increased by more than 30%, and the prevalence of asthma in children has increased by more than 10 times. Allergic diseases seriously affect people's health and quality of life.

[0003] Studies have shown that pollen from allergenic plants is one of the important allergens. Pollen from allergenic plants floating in the air is a trigger for seasonal rhinitis, conjunctivitis, and asthma, and is also an aggravating factor for atopic dermatitis.

[0004] Dexamethasone is a commonly used glucocorticoid with anti-inflammatory, anti-allergic, anti-shock and immunosuppressive effects, and plays an important role in the treatment of allergic diseases. Although dexamethasone is widely used in anti-allergic treatment, a small number of patients may have allergic reactions to the anti-allergic drug itself, manifested as rash, itching or severe anaphylactic shock. Long-term use of dexamethasone may cause some side effects, such as Cushing's syndrome, gastrointestinal ulcers, osteoporosis, increased risk of infection, etc. In addition, due to its high water solubility, dexamethasone is not suitable for nebulized inhalation therapy because it is difficult to bind to the glucocorticoid receptor through the cell membrane to exert a therapeutic effect.

[0005] Loratadine is a commonly used non-sedating second-generation antihistamine that is highly selective for peripheral nerve H1 receptors and can effectively relieve symptoms caused by allergic reactions, such as allergic rhinitis and chronic urticaria. However, there are also some defects in the treatment of allergic diseases with loratadine, such as drowsiness and central nervous system effects: although loratadine is relatively difficult to pass through the blood-brain barrier, it may still cause central nervous system effects such as drowsiness compared with other antihistamines; loratadine is metabolized by liver CYP450 enzymes, and when used in combination with certain drugs such as macrolide antibiotics and antifungal drugs such as ketoconazole, the blood concentration of loratadine may be increased, thereby increasing the risk of adverse reactions; long-term use of loratadine may cause side effects, including possible drug resistance.

[0006] β-1,3 / α-1,3-glucan is a polysaccharide made from sucrose and purified by Rhizobium pusa Rhizobium pusense ), alcohol precipitation, filtration, separation, drying, crushing and other processes. It is composed of glucose molecules connected alternately by β-1,3 and α-1,3 glycosidic bonds, with a clear structure and molecular formula: (C6H 10 O5)n, n≥615, purity≥90. This structure gives it unique biological activity and physical properties.

[0007] CN202211025241.2, Invention Name: Application of β-1,3 / α-1,3-glucan in the preparation of products for regulating skin microecology, the present invention discloses an application of β-1,3 / α-1,3-glucan in the preparation of products for regulating skin microecology. After research, it was found for the first time that the β-1,3 / α-1,3-glucan of the present invention can regulate skin microecology, improve the balance of skin microbial flora, regulate skin species diversity, maintain the stability of skin microecology, and maintain skin health. CN202111254517.X, Invention Name: Application of β-1,3 / α-1,3-glucan in the preparation of anti-ultraviolet sunscreen skin care products, discloses an application of β-1,3 / α-1,3-glucan in the preparation of anti-ultraviolet sunscreen skin care products. The present invention has proved through animal experiments that β-1,3 / α-1,3-glucan can increase the activity of antioxidant enzymes and slow down collagen degradation, and increase the skin's tolerance to ultraviolet rays. Application number: CN202310831089.5, invention name: β-1,3 / α-1,3-glucan composite composition with laxative function, preparation method and use thereof, providing a β-1,3 / α-1,3-glucan composite composition with laxative function, preparation method and use thereof, belonging to the field of functional food and medicine. The present invention provides a β-1,3 / α-1,3-glucan composite composition with laxative function, which is prepared from the following raw materials in a weight ratio: 1-2 parts of β-1,3 / α-1,3-glucan and 1-3 parts of Lactobacillus paracasei. The present invention also provides a preparation method and use of the composition. The composition of the present invention uses the raw materials in combination, has a laxative function, and plays a synergistic role in terms of the time of discharge of the first black stool.

[0008] There are currently no reports on the use of β-1,3 / α-1,3-glucan in the treatment of allergic diseases. Summary of the invention

[0009] The technical solution of the present invention is to provide a new use of beta-1,3 / alpha-1,3-glucan.

[0010] The present invention provides use of beta-1,3 / alpha-1,3-glucan in preparing medicine for treating or / and preventing allergic diseases.

[0011] Preferably, the drug is used in a drug for treating and / or preventing asthma.

[0012] Preferably, the drug is used in a drug for treating and / or preventing pollen allergy.

[0013] The drug is prepared into a commonly used pharmaceutical preparation by using β-1,3 / α-1,3-glucan as an active ingredient and adding pharmaceutically acceptable excipients or auxiliary ingredients.

[0014] Wherein, the preparation is an oral preparation.

[0015] The beta-1,3 / alpha-1,3-glucan of the present invention is used for treating and / or preventing allergic diseases, has clear efficacy, is equivalent to dexamethasone and loratadine in efficacy when used in high doses, and is safer in clinical use. DETAILED DESCRIPTION

[0016] Experimental Example 1 Effect of β-1,3 / α-1,3-glucan on asthmatic rats

[0017] Sixty SD male rats weighing 150-200g were randomly divided into 6 groups, namely normal control group, asthma model group, dexamethasone group (0.5 mg / kg), β-1,3 / α-1,3-glucan high, medium and low dose groups (50, 100, 200 mg / kg). The normal control group was intraperitoneally injected with 0.2 mL of normal saline on the first and seventh days, and the other groups were intraperitoneally injected with 0.2 mL of freshly prepared 0.1 mg / mL ovalbumin (OVA) normal saline (containing 5% aluminum hydroxide immune adjuvant) on the first and seventh days. On the eighth day, the rats except the normal control group were placed in the nebulizer box and nebulized with 1% OVA normal saline for 30 minutes each time. The normal control group was nebulized with normal saline. Starting from the 9th day, the β-1,3 / α-1,3-glucan group was gavaged according to the dose 2 hours before each challenge, the dexamethasone group was intraperitoneally injected with 0.5 mg / kg, and the normal control group and the model group were gavaged with 0.1 mL / 100 g of normal saline for 7 consecutive days. 24 hours after the last challenge, the rats were anesthetized by 10% chloral hydrate intraperitoneally, blood was collected through the abdominal aorta, serum was separated at 3000 rpm, and ELISA was used to determine Ig E, IL-4 and TNF-α (Table 1). After blood collection, the rats were killed, and the alveolar lavage fluid (BALF) was collected. The supernatant was separated and the precipitate was taken for leukocyte classification and counting (Table 2).

[0018] Table 1. Effects of β-1,3 / α-1,3-glucan on serum Ig E, IL-4 and TNF-α in asthmatic rats (n=10)

[0019] Group Ig E (ng / mL) TNF-α(ng / mL) IL-4 (ng / mL) Normal control group 2.49±0.12 126.77±6.11 52.33±2.68 Asthma model group <![CDATA[4.47±0.18 ## ]]> <![CDATA[155.65±3.47 ## ]]> <![CDATA[69.43±3.6 ## ]]> Positive drug group <![CDATA[2.63±0.14 ** ]]> <![CDATA[126.82±7.01 ** ]]> <![CDATA[51.98±3.01 ** <!-- 2 -->]]> Low dose group (50 mg / kg) 4.04±0.28 <![CDATA[142.54±6.51 * ]]> 65.21±1.99 Medium dose group (100 mg / kg) <![CDATA[3.57±0.26 * ]]> <![CDATA[136.62±5.89 ** ]]> <![CDATA[57.81±2.78 * ]]> High dose group (200 mg / kg) <![CDATA[2.99±0.22 ** ]]> <![CDATA[130.23±2.53 ** ]]> <![CDATA[53.37±3.00 ** ]]>

[0020] ## Model group vs normal group P<0.01; * Drug group vs model group P < 0.05; ** Drug group vs model group P<0.01

[0021] The levels of serum Ig E, IL-4 and TNF-α in rats in the asthma model group increased significantly. Compared with the model group, the 100 and 200 mg / kg β-1,3 / α-1,3-glucan groups could significantly reduce the levels of serum Ig E, IL-4 and TNF-α in asthma rats; the 50 mg / kg β-1,3 / α-1,3-glucan group could significantly reduce the level of serum TNF-α in asthma rats. The high-dose β-1,3 / α-1,3-glucan group had comparable efficacy to the positive drug dexamethasone group.

[0022] Table 2 Effects of β-1,3 / α-1,3-glucan on the differential count of leukocytes in BALF of asthmatic rats (n=10)

[0023] Group <![CDATA[Lymphocytes (10 9 / L)]]> <![CDATA[Eosinophils (10 9 / L)]]> <![CDATA[Neutrophils (10 9 / L)]]> Normal control group 19.7±1.6 2.9±0.2 69.8±5.1 Asthma model group 52.2±4.5** 10.7±1.0** 46.7±3.4** Positive drug group <![CDATA[24.3±2.9 ** ]]> <![CDATA[3.9±0.5 ** ]]> <![CDATA[59.1±3.9 ** ]]> Low dose group (50 mg / kg) 50.1±3.0 <![CDATA[8.9±0.4 * ]]> 47.6±2.8 Medium dose group (100 mg / kg) <![CDATA[39.1±2.8 ** ]]> <![CDATA[8.2±0.4 * ]]> <![CDATA[50.8±3.1 * ]]> High dose group (200 mg / kg) <![CDATA[32.2±1.6 ** ]]> <![CDATA[7.1±0.2 ** ]]> <![CDATA[56.7±3.0 ** ]]>

[0024] **Model group vs normal group P < 0.01; * Drug group vs model group P < 0.05; ** Drug group vs model group P<0.01

[0025] The number of lymphocytes and eosinophils in BALF of rats in the asthma model group increased significantly, and the number of neutrophils decreased significantly. Compared with the model group, β-1,3 / α-1,3-glucan 200 and 100 mg / kg could significantly reduce the number of lymphocytes and eosinophils in BALF of asthmatic rats, and significantly increase the number of neutrophils; β-1,3 / α-1,3-glucan 50 mg / kg could significantly reduce the number of eosinophils in asthmatic rats.

[0026] Experimental Example 2 Effects of β-1,3 / α-1,3-glucan on rats allergic to poplar pollen

[0027] Sixty male SD rats weighing 150-200g were randomly divided into 6 groups, namely normal control group, pollen allergy model group, loratadine (0.9 mg / kg) group, β-1,3 / α-1,3-glucan high, medium and low dose groups (50, 100, 200 mg / kg). The normal control group was intraperitoneally injected with 0.4 mL of normal saline, and the model group was intraperitoneally injected with 0.4 mL of 3.0 mg / mL poplar pollen crude extract in normal saline (containing 5% aluminum hydroxide immune adjuvant). Sensitization was repeated once every 5 days for a total of 4 times. On the fifth day after the fourth sensitization, the normal control group was given 100 μL of saline drops once a day for 7 consecutive days; the model group was given 100 μL of 10 mg / mL poplar pollen crude extract drops once a day for 7 consecutive days; 30 minutes before each nasal challenge, the β-1,3 / α-1,3-glucan group was gavaged according to the dose, the loratadine group was gavaged at a dose of 0.9 mg / kg, and the normal control group and the model group were gavaged with 0.1 mL / 100g of saline for 7 consecutive days. 24 hours after the last challenge, the rats were anesthetized with 10% chloral hydrate intraperitoneally, blood was collected through the abdominal aorta, serum was separated at 3000 rpm, and Ig E and IL-4 were measured by ELISA (Table 3).

[0028] Table 3 Effects of β-1,3 / α-1,3-glucan on serum Ig E and IL-4 in rats sensitized to pollen

[0029] Group Ig E (ng / mL) IL-4 (ng / mL) Normal control group 6.49±0.62 152.33±9.68 Pollen allergy model group <![CDATA[19.23±0.78 ## ]]> <![CDATA[193.43±4.6 ## ]]> Positive drug group <![CDATA[8.25±0.84 ** ]]> <![CDATA[155.55±3.01 ** ]]> Low dose group (50 mg / kg) <![CDATA[16.11±0.58 * ]]> 186.21±3.99 Medium dose group (100 mg / kg) <![CDATA[12.33±0.36 ** ]]> <![CDATA[169.81±2.98 ** ]]> High dose group (200 mg / kg) <![CDATA[7.99±0.32 ** ]]> <![CDATA[138.37±3.20 ** ]]>

[0030] ## Model group vs normal group P < 0.01; * Drug group vs model group P < 0.05; ** Drug group vs model group P<0.01

[0031] Compared with the normal control group, the IL-4 content of serum Ig E in rats in the pollen allergy model group increased significantly. Compared with the model group, the 100 and 200 mg / kg β-1,3 / α-1,3-glucan groups could significantly reduce the serum Ig E and IL-4 content of pollen allergy rats, and the efficacy of the high-dose group was equivalent to that of the positive drug loratadine; the 50 mg / kg β-1,3 / α-1,3-glucan group (low dose) could significantly reduce the serum Ig E level of pollen allergy rats.

Claims

1. Use of β-1,3 / α-1,3-glucan in the preparation of drugs for treating and / or preventing allergic diseases; the allergic diseases are asthma or pollen allergy.

2. The use according to claim 1, characterized in that: The medicine is prepared into a commonly used pharmaceutical preparation by taking beta-1,3 / alpha-1,3-glucan as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.

3. The use according to claim 2, characterized in that: The preparation is an oral preparation.

Citation Information

Cited By

  • Application of beta-1, 3 / alpha-1, 3-glucan in preparation of medicine for treating or / and preventing chronic rhinitis

    CN120771175A